Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and rare diseases, has announced encouraging interim findings from its ongoing Phase 2 open-label STARBORN-1 trial. The study evaluates the intracystic administration of TARA-002, the company’s

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) have announced that the U.S. FDA has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab‑dpzb) 420 mg/14 mL injection for intravenous administration. This interchangeable biosimilar to PERJETA (pertuzumab) is approved for all